Dr. Catherine A. Long
Claim this profileSaint Vincent Hospital Cancer Center Green Bay
Studies Cancer
Studies Leukemia
24 reported clinical trials
60 drugs studied
About Catherine A. Long
Education:
- Earned a Medical degree (MD) from an accredited medical school.
- Completed Residency in Internal Medicine at a recognized institution.
- Undertook a Fellowship in Hematology/Oncology at the University of Wisconsin School of Medicine and Public Health.
Experience:
- Currently practices as a hematologist and oncologist at Saint Vincent Hospital Cancer Center in Green Bay.
Area of expertise
1Cancer
Stage I
Stage IV
Stage II
2Leukemia
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Catherine A. Long is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Triptorelin
for Cancer
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting2 awards Phase 34 criteria
More about Catherine A. Long
Clinical Trial Related6 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Catherine A. Long has experience with
- Cyclophosphamide
- Etoposide
- Mercaptopurine
- Vincristine Sulfate
- Dexamethasone
- Daunorubicin Hydrochloride
Breakdown of trials Catherine A. Long has run
Cancer
Leukemia
Burkitt Lymphoma
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Catherine A. Long specialize in?
Catherine A. Long focuses on Cancer and Leukemia. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Catherine A. Long currently recruiting for clinical trials?
Yes, Catherine A. Long is currently recruiting for 9 clinical trials in Green Bay Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Catherine A. Long has studied deeply?
Yes, Catherine A. Long has studied treatments such as Cyclophosphamide, Etoposide, Mercaptopurine.
What is the best way to schedule an appointment with Catherine A. Long?
Apply for one of the trials that Catherine A. Long is conducting.
What is the office address of Catherine A. Long?
The office of Catherine A. Long is located at: Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin 54301 United States. This is the address for their practice at the Saint Vincent Hospital Cancer Center Green Bay.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.